Article
Targeting hypoxic habitats with hypoxia pro-drug evofosfamide in preclinical models of sarcoma
2020-10-07
Abstract excerpt
Hypoxic regions (habitats) within tumors are heterogeneously distributed and can be widely variant. Hypoxic habitats are generally pan-therapy resistant. For this reason, hypoxia-activated prodrugs (HAPs) have been developed to target these resistant volumes. The HAP evofosfamide (TH-302) has shown promise in preclinical and early clinical trials of sarcoma. However, in a phase III clinical trial, TH-302 did not i...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 6cc6c05c-887e-517b-9654-3c2117632b8b
- DOI
- 10.1101/2020.10.06.326934
